Emerald Acquisition Ltd. purchased a new stake in shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 59,612 shares of the specialty pharmaceutical company’s stock, valued at approximately $779,000. Emerald Acquisition Ltd. owned about 0.12% of SciClone Pharmaceuticals as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of SCLN. New York State Teachers Retirement System raised its position in SciClone Pharmaceuticals by 858.6% in the second quarter. New York State Teachers Retirement System now owns 41,221 shares of the specialty pharmaceutical company’s stock valued at $538,000 after buying an additional 36,921 shares during the period. Fox Run Management L.L.C. acquired a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $180,000. Eqis Capital Management Inc. acquired a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $331,000. Capstone Asset Management Co. acquired a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $197,000. Finally, BNP Paribas Arbitrage SA acquired a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $204,000. 79.60% of the stock is owned by institutional investors and hedge funds.
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) traded down 0.40% on Friday, hitting $9.98. 38,066 shares of the stock traded hands. The stock has a 50-day moving average of $10.30 and a 200-day moving average of $11.83. The firm has a market cap of $498.39 million, a price-to-earnings ratio of 13.47 and a beta of 1.47. SciClone Pharmaceuticals Inc. has a 12-month low of $7.13 and a 12-month high of $15.02.
SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share for the quarter. SciClone Pharmaceuticals had a net margin of 24.02% and a return on equity of 24.43%. The business earned $39 million during the quarter, compared to analysts’ expectations of $37.90 million. Analysts forecast that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current year.
In related news, CEO Friedhelm Blobel sold 501,875 shares of the company’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $10.00, for a total transaction of $5,018,750.00. Following the completion of the transaction, the chief executive officer now directly owns 588,255 shares in the company, valued at approximately $5,882,550. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the company’s stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $10.62, for a total transaction of $82,857.24. Following the transaction, the chief financial officer now owns 25,000 shares of the company’s stock, valued at $265,500. The disclosure for this sale can be found here. 7.63% of the stock is currently owned by insiders.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals Inc. (NASDAQ:SCLN).
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.